Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
23andMe Holding Co. - Common Stock
(NQ:
ME
)
0.6063
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Mar 28, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about 23andMe Holding Co. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
23andMe Therapeutics Announces Positive In Vivo Results for 23ME-01473, a Dual-Mechanism ULBP6-Targeting Antibody Currently in a Phase 1 Trial
September 15, 2024
From
23andMe, Inc.
Via
GlobeNewswire
23andMe Therapeutics Announces Phase 2 Results for Two Additional Cancer Cohorts and Correlative Biomarker Data from 23ME-00610 Study
September 15, 2024
From
23andMe, Inc.
Via
GlobeNewswire
One of the Largest and Most Diverse Studies on Sickle Cell Trait and Blood Clots Reveals Findings That Impact All Populations
September 12, 2024
23andMe, National Human Genome Research Institute, and Johns Hopkins University conducted collaborative research that studied sickle cell trait in a diverse population
From
23andMe, Inc.
Via
GlobeNewswire
Looking Into 23andMe Holding's Recent Short Interest
↗
June 12, 2024
Via
Benzinga
23andMe to Present Updates on Clinical Immuno-oncology Programs 23ME-00610 and 23ME-01473 at ESMO Congress 2024
September 03, 2024
From
23andMe, Inc.
Via
GlobeNewswire
Why Affirm Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
↗
August 29, 2024
Via
Benzinga
Lemonaid Health Now Offering GLP-1 Medication Through Weight Loss Membership Program
August 28, 2024
In conjunction with this new offering, 23andMe, Lemonaid Health’s parent company, recently launched study focused on the role genetics may play in effectiveness and side effects of GLP-1s
From
23andMe, Inc.
Via
GlobeNewswire
ME Stock Earnings: 23andMe Holding Beats EPS, Misses Revenue for Q1 2025
↗
August 08, 2024
ME stock results show that 23andMe Holding beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2025.
Via
InvestorPlace
23andMe Reports First Quarter Fiscal 2025 Financial Results
August 08, 2024
From
23andMe, Inc.
Via
GlobeNewswire
ME Stock Alert: CEO Anne Wojcicki Enters $200 Million Buyout Offer for 23andMe
↗
August 02, 2024
23andMe stock is up on Friday as investors react to an offer from the company's founder to take it private for 40 cents per share for ME.
Via
InvestorPlace
23andMe Special Committee responds to CEO’s take-private proposal
August 02, 2024
From
23andMe, Inc.
Via
GlobeNewswire
23andMe Announces CEO’s Take-Private Proposal
August 01, 2024
From
23andMe, Inc.
Via
GlobeNewswire
23andMe to Report Q1 FY2025 Financial Results
July 25, 2024
From
23andMe, Inc.
Via
GlobeNewswire
Twenty Lung Cancer Advocacy Organizations and 23andMe Come Together to Launch Lung Cancer Genetics Study to Help Advance Research
July 25, 2024
Study aims to build a comprehensive, open-source database of heritable genetics and patient-reported data in lung cancer
From
23andMe, Inc.
Via
GlobeNewswire
The 3 Best Personalized Nutrition Stocks to Buy Now
↗
July 24, 2024
Explore personalized nutrition stocks capitalizing on AI, machine learning and genetic profiling to provide targeted dietary solutions.
Via
InvestorPlace
Topics
Artificial Intelligence
23ANDME INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates 23andMe Holding Co. - ME
July 19, 2024
From
Kahn Swick & Foti, LLC
Via
Business Wire
3 High-Dividend Stocks to Buy if You Are Seeking Consistent Payouts
↗
July 11, 2024
Hercules Capital, Pfizer and Target offer stability, growth potential and reliable dividends in the realm of high-dividend stocks.
Via
InvestorPlace
23andMe And Nightingale Health Announce Strategic Collaboration To Pilot Blood Biomarker Panel
June 28, 2024
From
23andMe, Inc.
Via
GlobeNewswire
3 Ultra-High-Yield Dividend Stocks to Buy Hand Over Fist Right This Instant
↗
June 27, 2024
Business development companies can be a lucrative source of passive income.
Via
The Motley Fool
3 Penny Stocks That Can Deliver Over 5,000% Upside by 2025: June Edition
↗
June 11, 2024
Don’t miss out on these three penny stocks, which have amazing potential to take off following upcoming business developments this year.
Via
InvestorPlace
23andMe Launches New Genetic Report on Bipolar Disorder
June 05, 2024
Provides 23andMe+ Premium members with insight into their likelihood of developing the serious mental health illness based on thousands of genetic variants
From
23andMe, Inc.
Via
GlobeNewswire
Why 23andMe Stock Tumbled 10% on Tuesday
↗
June 04, 2024
Is altruism a good idea for an unprofitable capitalistic enterprise?
Via
The Motley Fool
23andMe and the Colorectal Cancer Alliance Collaborate to Help Advance Colorectal Cancer Research in the Black Community
June 04, 2024
Study aims to fill research gap and empower people through access to information about their health
From
23andMe, Inc.
Via
GlobeNewswire
23andMe Therapeutics Announces Positive Preliminary Phase 2 Safety and Efficacy Results for 23ME-00610, targeting CD200R1, at the 2024 ASCO Annual Meeting
June 03, 2024
From
23andMe, Inc.
Via
GlobeNewswire
Largest study on the LRRK2 variant leads to discoveries about health, ancestry, and history
May 29, 2024
Findings from 23andMe research on Parkinson’s disease published in Brain
From
23andMe, Inc.
Via
GlobeNewswire
ME Stock Earnings: 23andMe Holding Beats EPS, Beats Revenue for Q4 2024
↗
May 23, 2024
ME stock results show that 23andMe Holding beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2024.
Via
InvestorPlace
12 Health Care Stocks Moving In Thursday's After-Market Session
↗
May 23, 2024
Via
Benzinga
23andMe Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results
May 23, 2024
From
23andMe, Inc.
Via
GlobeNewswire
Lemonaid Health Now Offers Prescription ED Medication STENDRAⓇ Through Collaboration with Petros Pharmaceuticals
May 14, 2024
Lemonaid Health will offer customers more affordable access to fast-acting branded ED medication that works as quickly as 15 minutes prior to sexual activity
From
23andMe, Inc.
Via
GlobeNewswire
23andMe to Report Q4 and Full Year FY2024 Financial Results
May 09, 2024
From
23andMe, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
